A feud between Prime Medicine and Tessera Therapeutics, two gene-editing companies, has spilled out into public.

Prime editing, a versatile form of gene editing that can correct most known disease-causing genetic mutations, now has a new vehicle to deliver its machinery into cells in living animals.

The prime editor is a fusion protein consisting of a catalytically impaired Cas9 nickase (Cas9n) and an engineered reverse transcriptase (RT). The Cas9n is guided by a prime editing guide RNA (pegRNA) ...

Prime Medicine has been given the go-ahead by the FDA for the first human trial of its prime editing technology, which promises to deliver one-shot therapies for a range of severe genetic diseases.

to initiate trials of the first-ever prime editing drug. The FDA cleared Prime Medicine’s investigational new drug (IND) ...

2024 — New research has determined the spatial structure of various processes of a novel gene-editing tool called 'prime editor.' Functional analysis based on these structures also revealed how a ...

Prime has granted to BMS an exclusive worldwide license to its Prime Editing technology, through which Prime agreed to design Prime Editing reagents through its Prime Assisted Site-Specific ...

Prime Medicine, a biotech company that set out to use its more precise approach to gene editing to develop new one-time treatments for rare diseases, is expanding its scope to more prevalent ...

“We founded Prime Medicine with a singular vision: to apply our groundbreaking Prime Editing platform to address the genetic causes of debilitating diseases and provide patients with long ...

Prime Medicine is to use its Prime Editor gene-editing platform to develop these reagents for its partner. In its press release trumpeting the deal, Prime Medicine quoted CEO Keith Gottesdiener as ...

Gene-editing biotech Prime Medicine has priced a follow-on public offering, hoping to raise $140 million to advance its pipeline of one-shot therapies for severe genetic disorders. The Cambridge ...

This funding, provided through the NIH’s Somatic Cell Genome Editing Program, will support gene-editing research aimed at ...